Immunology / Virology & Vaccines

#Academic #Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #RNA #Stem cells

Study shows Oxford coronavirus vaccine produces strong immune response

A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Clinical trials #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

UK secures portfolio of promising vaccines candidates from BioNTech/Pfizer alliance

Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising Covid-19 vaccine candidates. The UK government has agreed significant partnerships with leading pharmaceutical and vaccine companies BioNTech/Pfizer and Valneva that are developing new vaccines to protect people against… Read More

#Covid-19 #News

#Academic #Analysis #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #Pharmacology #Screening #System biology #Systems biology #Therapeutics

Remotely accessible assays help researchers work from home

Scientists in academic centres and companies around the world desperately search for novel therapeutics and vaccines to treat and prevent COVID-19. However, with lockdowns and limited access to laboratories, researchers are being forced to work from home, putting research continuity at risk. To help scientists continue their R&D,… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Precision medicine #Preclinical #RNA #Therapeutics #Translational #Translational chemistry

Cancer vaccine shows promising signs

The Translational Research Institute-based Mater researchers in partnership with The University of Queensland have developed a new cancer vaccine, which has shown promising signs in preclinical laboratory studies. Funded by grants from the Worldwide Cancer Research in the United Kingdom, and Mater Foundation, the new vaccine could be potentially… Read More

#Covid-19 #News

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug discovery #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Oncology #Screening #Therapeutics

DDW summer issue now out

2 July 2020 From the race to the COVID-19 cure to the new manufacturing technologies that could be a game changer for stem cell therapies. With COVID-19 still a significant feature in the drug discovery landscape, this issue looks at the race to finding a cure – from… Read More

#News

#Business #Clinical trials #Drug development #Drug discovery #Immunology / Virology & Vaccines #RNA

Symbiosis secures £1 million of growth finance from Allied Irish Bank

1 July 2020 Image: Micheile Henderson Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy. Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Engineers use ‘DNA origami’ to identify vaccine design rules

30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune… Read More

#News

#Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Precision medicine #RNA

Symbiosis to manufacture COVID-19 vaccine for clinical trials

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials. Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology / Virology & Vaccines #RNA

Cobra Biologics signs manufacture agreement with AstraZeneca for COVID-19 vaccine candidate

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based… Read More

#Covid-19 #News

#Analysis #Biologics / Biotechnology #Business #Clinical trials #Drug discovery #Imaging #Immunology / Virology & Vaccines

Novasep teams up with AstraZeneca to produce COVID-19 vaccine for Europe

Novasep, viral vector producer, has signed a partnership with AstraZeneca for the production of the Oxford University COVID-19 vaccine. Novasep will produce the active substance of the vaccine in its Belgian facilities The partnership follows the agreement between AstraZeneca and the Inclusive Alliance for Vaccines (IAV), to supply… Read More

#Covid-19 #News

#Business #Cell therapy #Clinical trials #Gene therapy #Immunology / Virology & Vaccines

Oxford Biomedica agreement with Vaccines Manufacturing and Innovation Centre

8 June, 2020 The UK based gene and cell therapy group announced that it has signed a collaboration agreement on June 8 with the Vaccines Manufacturing and Innovation Centre (VMIC) to provide the UK’s first strategic vaccine development and advanced manufacturing capability. According to Oxford Biomedica, the five-year… Read More

#News

#Academic #Biomarkers #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Pathology #Pharmokinetics #Stem cells

Creoptix collaboration to characterise anti-SARS-CoV-2 antibodies

15 May, 2020 The Swiss next-generation bioanalytical instruments specialist announced a collaboration with Adriano Aguzzi, Professor for Neuropathology, University of Zurich, to characterise immunological responses to SARS-CoV-2 such as IgA, IgM and IgG antibodies, which signal whether an individual has been exposed to the coronavirus. The collaboration aims… Read More

#News

#Animal models #Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #Genetics / genomes #Immunology / Virology & Vaccines #Regulatory #RNA

Insect-based technology for human vaccines

06 May, 2020 Spain based private biotechnology company Algenex announced that it is advancing the application of its CrisBio-based vaccine production technology in human health. Building on its expertise in the production of proteins for veterinary vaccines, Algenex said it has started to produce biotechnology products for the… Read More

#News

#Cell therapy #Clinical specialities #Drug development #Immunology #Immunology / Virology & Vaccines #Oncology #RNA #Stem cells

NanoPass shares Micronjet technology with global partners

The Israel based developer of nearly painless intradermal delivery solutions for vaccines and drugs said it is joining forces with leading vaccine and immunotherapy companies worldwide to share its proprietary MicronJet microneedle device. According to NanoPass, the aim is to enable the development of a safe, effective and… Read More

#Covid-19 #News

#Business #Clinical specialities #Clinical trials #High Content Screening #Immunology #Immunology / Virology & Vaccines #RNA

Agreement for research grade bioreagents for SARS-CoV-2 vaccine

GeoVax Labs, a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced on April 30 that Beijing- and Philadelphia-based Sino Biological, will be its exclusive supplier of SARS-CoV-2 (Covid-19) bioreagent research products. Under the terms of the agreement, Sino Biological will provide… Read More

#Covid-19 #News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Precision medicine #RNA

Oxford University and AstraZeneca partner for COVID-19 vaccine candidate

Oxford University and its spin-out company Vaccitech announced an agreement with UK based biopharmaceutical specialist AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate, currently being trialled by the University. With immediate effect, the partnership is said to allow for rapid vaccination… Read More

#Covid-19 #News